Pure Rheumatology London Expands Osteoporosis Care With IV Zoledronate Infusions At One Welbeck
Zoledronate (Zoledronic Acid) is a clinically proven treatment for osteoporosis that strengthens bones, reduces fracture risk, and improves long-term bone health. Delivered as a once-yearly intravenous infusion, it offers patients an effective and convenient alternative to daily or weekly tablets.
Patients receiving IV Zoledronate at Pure Rheumatology London benefit from:
Expert assessment and diagnosis of osteoporosis and other metabolic bone disorders
On-site infusion therapy performed by experienced rheumatology specialists
Cutting-edge facilities at One Welbeck, designed to optimise safety and patient comfort
Comprehensive follow-up including bone density monitoring and personalised care plans
Unlike traditional NHS pathways where waiting times can delay treatment, Pure Rheumatology London ensures rapid appointments, same-day investigations, and seamless access to infusions . Patients can be assessed, diagnosed, and treated promptly under the guidance of a consultant rheumatologist.
A Commitment to Excellence at One Welbeck Dr Naveen Bhadauria, Consultant Rheumatologist at Pure Rheumatology London , said:
“Our goal is to provide patients with the very best care in osteoporosis management. By offering IV Zoledronate infusions at One Welbeck, we are combining a highly effective treatment with one of London's finest medical environments, ensuring patients receive timely, safe, and expert-led care.”
Pure Rheumatology London is a specialist private rheumatology practice dedicated to the diagnosis and management of arthritis, autoimmune diseases, musculoskeletal pain, and bone health conditions. With clinics at One Welbeck and The Shard HCA , the practice offers rapid diagnosis, advanced treatments, and compassionate, patient-focused care .
For more information or to book an appointment for an IV Zoledronate infusion at One Welbeck , please visit:
Media Contact:
Pure Rheumatology London
Email: ...
Phone:02071267264

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Market Research

- Gas Engine Market Analysis: Strong Growth Projected At 3.9% CAGR Through 2033
- Daytrading Publishes New Study On The Dangers Of AI Tools Used By Traders
- Excellion Finance Launches MAX Yield: A Multi-Chain, Actively Managed Defi Strategy
- United States Lubricants Market Growth Opportunities & Share Dynamics 20252033
- ROVR Releases Open Dataset To Power The Future Of Spatial AI, Robotics, And Autonomous Systems
- Blackrock Becomes The Second-Largest Shareholder Of Freedom Holding Corp.
Comments
No comment